Pancreatic Cancer Biomarkers and Their Implication in Cancer Diagnosis and Epidemiology

Pancreatic cancer is the fourth most common cause of cancer-related mortality in the United States. Biomarkers are needed to detect this cancer early during the disease development and for screening populations to identify those who are at risk. In cancer, “biomarker” refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker might be either a molecule secreted by a tumor or it can be a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. A number of potential biomarkers have been identified for pancreatic cancer. These markers can be assayed in non-invasively collected biofluids. These biomarkers need analytical and clinical validation so that they can be used for the purpose of screening and diagnosing pancreatic cancer and determining disease prognosis. In this article, the latest developments in pancreatic cancer biomarkers are discussed.

[1]  Michelle A. Anderson,et al.  Reliable gene expression measurements from fine needle aspirates of pancreatic tumors: effect of amplicon length and quality assessment. , 2010, The Journal of molecular diagnostics : JMD.

[2]  M. Lerner,et al.  Biomarker Identification in Human Pancreatic Cancer Sera , 2008, Pancreas.

[3]  G. Gonye,et al.  HuR Status is a Powerful Marker for Prognosis and Response to Gemcitabine-Based Chemotherapy for Resected Pancreatic Ductal Adenocarcinoma Patients , 2010, Annals of surgery.

[4]  Eithne Costello,et al.  A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ. , 2009, Journal of proteomics.

[5]  Y. Gong,et al.  Identification of pancreatic juice proteins as biomarkers of pancreatic cancer. , 2010, Oncology reports.

[6]  Eithne Costello,et al.  Pancreatic Cancer: Proteomic Approaches to a Challenging Disease , 2009, Pancreatology.

[7]  M. Verma.  Pancreatic Cancer Epidemiology , 2005, Technology in cancer research & treatment.

[8]  R. Hruban,et al.  PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma , 2007, Clinical Cancer Research.

[9]  S. Maehara,et al.  Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. , 2007, International journal of oncology.

[10]  Quynh-Thu Le,et al.  Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. , 2010, Translational oncology.

[11]  M. Verma.  Proteomics and cancer epidemiology. , 2009, Methods in molecular biology.

[12]  C. Verbeke,et al.  Pathology of pancreatic tumours , 2010 .

[13]  H. Brenner,et al.  Stool testing for the early detection of pancreatic cancer: rationale and current evidence , 2008, Expert review of molecular diagnostics.

[14]  D. Albanes,et al.  Serum pepsinogen level, atrophic gastritis and the risk of incident pancreatic cancer--a prospective cohort study. , 2009, Cancer epidemiology.

[15]  C. Iacobuzio-Donahue,et al.  Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer , 2010, British Journal of Cancer.

[16]  G. V. Vande Woude,et al.  Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer , 2010, Molecular Cancer Therapeutics.

[17]  Debra T Silverman,et al.  Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 Molar Ratio and Risk of Pancreatic Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[18]  K. Lance,et al.  Utility of cells exfoliated onto the esophagoscope as an aid in the diagnosis of esophageal carcinoma , 2005, The American Journal of Digestive Diseases.

[19]  M. Verma.  Biomarkers for Risk Assessment in Molecular Epidemiology of Cancer , 2004, Technology in cancer research & treatment.

[20]  W. Greenhalf,et al.  Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer , 2010, British Journal of Cancer.

[21]  R. Aebersold,et al.  Proteomics studies of pancreatic cancer , 2007, Proteomics. Clinical applications.

[22]  R. Zeillinger,et al.  New and potential clinical applications of KRAS as a cancer biomarker. , 2010, Expert opinion on medical diagnostics.

[23]  K. Sugano.  [Molecular diagnosis of pancreatic cancer]. , 1997, Nihon Geka Gakkai zasshi.

[24]  M. Verma,et al.  Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations. , 2006, Critical reviews in oncology/hematology.

[25]  D. Seminara,et al.  Genetic and Epigenetic Biomarkers in Cancer , 2012, Molecular Diagnosis & Therapy.

[26]  G. Hostetter,et al.  Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray. , 2010, Biochemical pharmacology.

[27]  Gilbert S. Omenn,et al.  Alternative Splice Variants, a New Class of Protein Cancer Biomarker Candidates: Findings in Pancreatic Cancer and Breast Cancer with Systems Biology Implications , 2010, Disease markers.

[28]  L. Miller,et al.  A novel secretin receptor splice variant potentially useful for early diagnosis of pancreatic carcinoma. , 2007, Gastroenterology.

[29]  Y. Gong,et al.  Detection of Differentially Expressed microRNAs in Serum of Pancreatic Ductal Adenocarcinoma Patients: miR-196a Could Be a Potential Marker for Poor Prognosis , 2011, Digestive Diseases and Sciences.

[30]  B. Nelson,et al.  Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia , 2010, Molecular Cancer.

[31]  C. Logsdon,et al.  Progress on molecular markers of pancreatic cancer , 2007, Current opinion in gastroenterology.

[32]  C. Hajdu,et al.  Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma. , 2010, Anticancer research.

[33]  Yong-Tae Kim,et al.  Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer , 2010, PloS one.

[34]  R Margreiter,et al.  High expression of TROP2 correlates with poor prognosis in pancreatic cancer , 2008, British Journal of Cancer.

[35]  H. Friess,et al.  Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. , 2008, European journal of cancer.

[36]  H. Banerjee,et al.  Epigenetic mechanisms in cancer. , 2009, Biomarkers in medicine.

[37]  Yusuke Nakamura,et al.  Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma , 2009, Journal of Gastroenterology.

[38]  Jeong-A Lim,et al.  α-Syntrophin Modulates Myogenin Expression in Differentiating Myoblasts , 2010, PloS one.

[39]  J. Ajani,et al.  Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. , 2010, Biomarkers in medicine.

[40]  R. Andersson,et al.  Diabetes Mellitus in Pancreatic Cancer and the Need for Diagnosis of Asymptomatic Disease , 2010, Pancreatology.

[41]  David Elashoff,et al.  Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. , 2010, Gastroenterology.

[42]  D. Albanes,et al.  Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. , 2008, American journal of epidemiology.

[43]  B. Sitek,et al.  Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation. , 2009, Journal of proteome research.

[44]  M. Reni.  Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? , 2010, World journal of gastroenterology.

[45]  S. Teutsch,et al.  The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group , 2009, Genetics in Medicine.